161 related articles for article (PubMed ID: 16519963)
1. Structural determinants of phosphodiesterase 6 response on binding catalytic site inhibitors.
Simon A; Barabás P; Kardos J
Neurochem Int; 2006 Aug; 49(3):215-22. PubMed ID: 16519963
[TBL] [Abstract][Full Text] [Related]
2. Critical amino acids in phosphodiesterase-5 catalytic site that provide for high-affinity interaction with cyclic guanosine monophosphate and inhibitors.
Zoraghi R; Francis SH; Corbin JD
Biochemistry; 2007 Nov; 46(47):13554-63. PubMed ID: 17979301
[TBL] [Abstract][Full Text] [Related]
3. Homology modeling, docking studies and molecular dynamic simulations using graphical processing unit architecture to probe the type-11 phosphodiesterase catalytic site: a computational approach for the rational design of selective inhibitors.
Cichero E; D'Ursi P; Moscatelli M; Bruno O; Orro A; Rotolo C; Milanesi L; Fossa P
Chem Biol Drug Des; 2013 Dec; 82(6):718-31. PubMed ID: 23865680
[TBL] [Abstract][Full Text] [Related]
4. Radiolabeled ligand binding to the catalytic or allosteric sites of PDE5 and PDE11.
Weeks JL; Blount MA; Beasley A; Zoraghi R; Thomas MK; Sekhar KR; Corbin JD; Francis SH
Methods Mol Biol; 2005; 307():239-62. PubMed ID: 15988068
[TBL] [Abstract][Full Text] [Related]
5. A proline-rich domain in the gamma subunit of phosphodiesterase 6 mediates interaction with SH3-containing proteins.
Morin F; Vannier B; Houdart F; Regnacq M; Berges T; Voisin P
Mol Vis; 2003 Sep; 9():449-59. PubMed ID: 14502124
[TBL] [Abstract][Full Text] [Related]
6. Mutation in rod PDE6 linked to congenital stationary night blindness impairs the enzyme inhibition by its gamma-subunit.
Muradov KG; Granovsky AE; Artemyev NO
Biochemistry; 2003 Mar; 42(11):3305-10. PubMed ID: 12641462
[TBL] [Abstract][Full Text] [Related]
7. A 46-amino acid segment in phosphodiesterase-5 GAF-B domain provides for high vardenafil potency over sildenafil and tadalafil and is involved in phosphodiesterase-5 dimerization.
Blount MA; Zoraghi R; Ke H; Bessay EP; Corbin JD; Francis SH
Mol Pharmacol; 2006 Nov; 70(5):1822-31. PubMed ID: 16926278
[TBL] [Abstract][Full Text] [Related]
8. Conversion of phosphodiesterase-5 (PDE5) catalytic site to higher affinity by PDE5 inhibitors.
Blount MA; Zoraghi R; Bessay EP; Beasley A; Francis SH; Corbin JD
J Pharmacol Exp Ther; 2007 Nov; 323(2):730-7. PubMed ID: 17690252
[TBL] [Abstract][Full Text] [Related]
9. The regulatory subunit of PDE6 interacts with PACSIN in photoreceptors.
Houdart F; Girard-Nau N; Morin F; Voisin P; Vannier B
Mol Vis; 2005 Dec; 11():1061-70. PubMed ID: 16357825
[TBL] [Abstract][Full Text] [Related]
10. Structural determinants for inhibitor specificity and selectivity in PDE2A using the wheat germ in vitro translation system.
Iffland A; Kohls D; Low S; Luan J; Zhang Y; Kothe M; Cao Q; Kamath AV; Ding YH; Ellenberger T
Biochemistry; 2005 Jun; 44(23):8312-25. PubMed ID: 15938621
[TBL] [Abstract][Full Text] [Related]
11. Functional characterization of the non-catalytic ectodomains of the nucleotide pyrophosphatase/phosphodiesterase NPP1.
Gijsbers R; Ceulemans H; Bollen M
Biochem J; 2003 Apr; 371(Pt 2):321-30. PubMed ID: 12533192
[TBL] [Abstract][Full Text] [Related]
12. Investigation of the relationship between protein-protein interaction and catalytic activity of a heme-regulated phosphodiesterase from Escherichia coli (Ec DOS) by protein microarray.
Sasakura Y; Kanda K; Yoshimura-Suzuki T; Matsui T; Fukuzono S; Shimizu T
Biochemistry; 2005 Jul; 44(28):9598-605. PubMed ID: 16008345
[TBL] [Abstract][Full Text] [Related]
13. Active site similarity between human and Plasmodium falciparum phosphodiesterases: considerations for antimalarial drug design.
Howard BL; Thompson PE; Manallack DT
J Comput Aided Mol Des; 2011 Aug; 25(8):753-62. PubMed ID: 21766240
[TBL] [Abstract][Full Text] [Related]
14. N-Terminal domain of phosphodiesterase-11A4 (PDE11A4) decreases affinity of the catalytic site for substrates and tadalafil, and is involved in oligomerization.
Weeks JL; Zoraghi R; Francis SH; Corbin JD
Biochemistry; 2007 Sep; 46(36):10353-64. PubMed ID: 17696499
[TBL] [Abstract][Full Text] [Related]
15. Crystal structure of the catalytic fragment of human brain 2',3'-cyclic-nucleotide 3'-phosphodiesterase.
Sakamoto Y; Tanaka N; Ichimiya T; Kurihara T; Nakamura KT
J Mol Biol; 2005 Feb; 346(3):789-800. PubMed ID: 15713463
[TBL] [Abstract][Full Text] [Related]
16. The mechanism of cyclic nucleotide hydrolysis in the phosphodiesterase catalytic site.
Salter EA; Wierzbicki A
J Phys Chem B; 2007 May; 111(17):4547-52. PubMed ID: 17425352
[TBL] [Abstract][Full Text] [Related]
17. Structural determinants of the PDE6 GAF A domain for binding the inhibitory gamma-subunit and noncatalytic cGMP.
Muradov H; Boyd KK; Artemyev NO
Vision Res; 2004; 44(21):2437-44. PubMed ID: 15358079
[TBL] [Abstract][Full Text] [Related]
18. Identification, synthesis and SAR of amino substituted pyrido[3,2b]pyrazinones as potent and selective PDE5 inhibitors.
Owen DR; Walker JK; Jon Jacobsen E; Freskos JN; Hughes RO; Brown DL; Bell AS; Brown DG; Phillips C; Mischke BV; Molyneaux JM; Fobian YM; Heasley SE; Moon JB; Stallings WC; Joseph Rogier D; Fox DN; Palmer MJ; Ringer T; Rodriquez-Lens M; Cubbage JW; Blevis-Bal RM; Benson AG; Acker BA; Maddux TM; Tollefson MB; Bond BR; Macinnes A; Yu Y
Bioorg Med Chem Lett; 2009 Aug; 19(15):4088-91. PubMed ID: 19540112
[TBL] [Abstract][Full Text] [Related]
19. Molecular modeling studies of pyridopurinone derivatives--potential phosphodiesterase 5 inhibitors.
Srivani P; Srinivas E; Raghu R; Sastry GN
J Mol Graph Model; 2007 Jul; 26(1):378-90. PubMed ID: 17307372
[TBL] [Abstract][Full Text] [Related]
20. Increased phosphodiesterase-5 expression is involved in the decreased vasodilator response to nitric oxide in cirrhotic rat livers.
Loureiro-Silva MR; Iwakiri Y; Abraldes JG; Haq O; Groszmann RJ
J Hepatol; 2006 May; 44(5):886-93. PubMed ID: 16545481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
